Azelnidipine protects myocardium in hyperglycemia-induced cardiac damage

BACKGROUND: Azelnidipine (AZL), a long-acting dihydropyridine-based calcium antagonist, has been recently approved and used for treating ischemic heart disease and cardiac remodeling after myocardial infarction, however, its effect on hyperglycemia-induced cardiac damage has not been studied. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Kain, Vasundhara, Kumar, Sandeep, Puranik, Amrutesh S, Sitasawad, Sandhya L
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004822/
https://www.ncbi.nlm.nih.gov/pubmed/21118576
http://dx.doi.org/10.1186/1475-2840-9-82

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004822/
https://www.ncbi.nlm.nih.gov/pubmed/21118576
http://dx.doi.org/10.1186/1475-2840-9-82

Ejemplares similares